Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

The Alaska state public health laboratory in Anchorage is seen on Wednesday, Nov. 30, 2022. The state lab is one of the sites in Anchorage where tests are conducted for transmitted infections. (Photo ...

Chronic hepatitis C is a growing health problem worldwide that has attracted increased attention in recent years. Treatment with peginterferon and ribavirin combination had previously been the ...

Hepatitis C infection. Computer illustration showing liver and close-up view of hepatitis C viruses. Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection ...

Hepatitis C and opioid use disorder are both chronic but treatable conditions. Yet many Americans living with this deadly combination aren’t offered treatment. Imagine going to your doctor with strep ...

Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...

Driven by the ongoing opioid epidemic and the sharing of needles, hepatitis C cases have been rising in the United States over the last decade, with the highest infection rates among young adults, ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

Adapted with permission from [44]. Null response HCV RNA decline <2 log 10 IU/ml from baseline at week 12 Partial response HCV RNA decline >2 log 10 IU/ml from baseline at week 12, but HCV RNA ...